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Discussion on Acute Vein Graft
Occlusion Intervention
We read with interest the State-of-the-Art paper on saphenous
vein graft (SVG) intervention by Lee et al. (1), and commend the
authors for a comprehensive review.
We would like to highlight that the review failed to mention the
management of ST-segment elevation myocardial infarction due
to acute SVG occlusion. Retrospective data (2,3) have confirmed
his area remains a particularly high-risk subset of SVG interven-
ion, with 30-day mortality at 14.3% and major adverse cardiac
vents rate of 36.8% at 1 year. These are significantly worse than
ontemporary outcomes of acute coronary syndrome from coronary
rtery culprit lesions. We previously presented (4) a case of an
4-year-old patient with an ST-segment elevation myocardial
nfarction of a thrombotic occlusion in the SVG to the posterior
escending artery, during which difficulty was encountered in
estoring and maintaining flow in the culprit vessel. Significant
ffort was focused on preventing no-reflow with: 1) continuation of
he upstream tirofiban infusion; and 2) manual (Export catheter,
edtronic Inc., Minneapolis, Minnesota) and mechanical throm-
ectomy (Angiojet rheolytic thrombectomy catheter, Medrad Inc.,
arrendale, Philadelphia). A distal embolic protection device
Emboshield Abbott Vascular, Santa Clara, California) was deliv-
red distal to the culprit lesion before the placement of a bare-
etal stent. The stent nonetheless led to no-reflow, necessitating
reatment with adenosine, verapamil, and nitrate intracoronary
nfusion through a local delivery balloon (ClearWay RX, Atrium
edical, Hudson, New Hampshire). The final result was TIMI
Thrombolysis In Myocardial Infarction) flow grade 3 with no
ocal complication. A 12-month clinical follow-up revealed no
eintervention or rehospitalization.
We feel that acute SVG occlusion deserves a special mention.
here is currently little data applicable to this group of patients, as
irtually all trials on the aforementioned pharmacotherapy (i.e.,
Ib/IIIa inhibitors, adenosine, verapamil) and devices (thrombus
spiration and distal embolic protection) excluded patients with
cute SVG occlusion. The significant thrombus burden in the
ulprit vessel makes a satisfactory procedural outcome difficult and
he resulting compromised epicardial flow impairs long-term
utcome (5). It is not foreseeable that robust evidence-based
uidelines will ever become available given this relatively infre-
uent occurrence. Interventional cardiologists may be resigned to
xtrapolate data from research on SVG and acute coronary
yndrome interventions and be resourceful in approaching these
esions using all the tools that are available in interventional
ardiology.
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Reply
We are grateful to Drs. Poon, Roati, and Walters for their interest
in our State-of-the-Art paper (1). Their case highlights the
complexities encountered during treatment of ST-segment eleva-
tion myocardial infarction (STEMI) due to saphenous vein graft
(SVG) thrombosis.
Acute occlusion of SVGs is commonly associated with extensive
atherosclerotic and thrombotic burden, which increases the risk of
distal embolization and no-reflow and, thus, death and myocardial
infarction (2). Aged SVGs develop a form of accelerated athero-
sclerosis in which the plaque composition is highly friable, often
described as having the consistency of “gruel” or “cottage cheese.”
As a result, glycoprotein IIb/IIIa inhibitors are ineffective, and
embolic protection devices remain the default therapy to prevent
periprocedural complications. Randomized trials have demon-
strated that, although these devices are helpful, they are
incapable of preventing all instances of distal embolization (3).
These considerations are likely to be even more relevant in the
case of an occluded SVG with STEMI, and once the SVG
occludes distally—given the lack of side branches—the SVG
often backfills extensively with thrombus. Fortunately, SVG oc-
clusion is responsible for 5% of STEMI (34 of 3,602 infarctions
in the HORIZONS-AMI [Harmonizing Outcomes with Revas-
S
D
A
W
E
P
Y
R
J
L
G
*
1
R
L
E
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 1 1 , 2 0 1 1 Letters to the Editor
N O V E M B E R 2 0 1 1 : 1 2 5 0 – 2
1251cularization and Stents in Acute Myocardial Infarction] trial) (4),
and, hopefully, this number will further decrease with the increas-
ing emphasis on pan-arterial revascularization.
We agree that, given its infrequent occurrence, it will be difficult
to accrue meaningful data on best treatments for STEMI from
adequately powered randomized trials. Absent such data, we
empirically recommend potent antiplatelet and antithrombotic
agents (in patients at low risk of bleeding) and liberal use of
intragraft vasodilators to prevent and treat no-reflow. Either
proximal or distal embolic protection devices should also routinely
be used, with consideration of aspiration or thrombectomy for
further debulking. Drug-eluting stents have now been shown to be
safe in SVGs and might decrease restenosis (5). Preferential
intervention of the native coronary arterial circulation (rather than
the occluded SVG) should always be considered as an alternative
route to reperfusing the myocardium and, if possible, will result in
higher acute success and late patency rates (6).
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Coronary Artery Bypass Graft
In-Hospital Mortality and Long-Term Follow-Up
We have read with great interest the paper from Brilakis et al. (1)
concerning percutaneous coronary interventions (PCI) following
coronary artery bypass graft (CABG). Patients with a previous
CABG constitute an extremely high-risk group with an increased
frequency of comorbidities and multivessel disease. Brilakis et al.
notice very well that patients undergoing bypass graft PCI have
higher-risk clinical characteristics. Our attention was especially
attracted to the very important and didactic conclusion that
compared with native coronary PCI, bypass graft PCI is indepen-
dently associated with higher in-hospital mortality, which relates
to our research that soon will be published by Xanthopoulou et al.
(2). Interestingly, the 2 papers supplement each other, as at this
retrospective analysis of 190 patients, we found that post-CABG
patients, undergoing graft compared with native vessel PCI have
worse long-term clinical outcome (follow-up with a median
duration of 28 months) in terms of major adverse cardiac events,
death, and repeat revascularization. Brilakis et al. also found that
saphenous vein graft PCI becomes more prevalent with longer
time intervals from CABG, a finding in accordance with our
results.
By contrast, although the efficacy of embolic protection devices
is proven, the investigators do not mention the frequency of their
use in the saphenous vein graft PCI population (3). Additionally,
it would be important to assess the amount of myocardium in
jeopardy following PCI in the 2 groups. According to our opinion,
it would be helpful to incorporate those parameters in the
multivariate analysis, as they could have influenced the clinical
outcome of those patients (4).
Disease progression to the native vessels (NV) or failure of
grafts due to similar mechanisms with NV atherosclerosis usually
lead to repeat coronary revascularizations (5). Furthermore, the
NV is recommended as the ideal target for PCI when diseased
grafts are 3 years old (6).
In conclusion, it is clear that regardless of the selection criteria
for the PCI target vessel, patients subjected to graft PCI have
worse in-hospital mortality than patients who had NV-PCI, and
these data could be enhanced with our results adding details about
long-term clinical outcome. Physicians should prefer a NV if PCI
is to be performed in a patient following CABG, if the anatomy of
the vessels of the heart is suitable for it.
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